NEW YORK (GBI Research), 17 May 2012 - The fast-growing therapeutics market for arthritis is expected to grow further in the coming years as many new companies rush to cater for rising incidence rates, according to a new report by pharmaceutical experts GBI Research.
The new report* examines how arthritis therapeutics are becoming a gigantic attraction in the global pharmaceutical industry as the condition is increasingly considered to be one of the most common causes of disabilities.
The rising incidence rates of osteoarthritis (OA), rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) have helped accelerate growth in the arthritis market, and several major global pharmaceutical and biotechnological companies are keen to make investments in this lucrative industry.
Pfizer, Amgen, Merck, Roche and Novartis have already upped their research and development efforts in the field, with the arthritis pipeline demonstrating several promising therapies. The current pipeline includes many small molecule drugs and biologic therapies, as well as novel oral Disease-Modifying Anti-rheumatic Drugs (DMARDs), such as Tofacitinib, by Pfizer. Patients will not have a long wait for these novel new therapies, as 10% of the market’s prospective drugs were already in the late stage of development by the end of 2011.
A major trend in the arthritis market is the expansion of biologics as a treatment option. Biologics are prescribed for most arthritis indications, and, with the increased incidence of disease, biologics will drive the growth of the arthritis therapeutics market further during the coming years. Competition will be fierce for manufacturers, however, as the rapid entry of new players and the highly active pipeline will intensify the tussle for market share in the global arthritis market.
It’s not all bad news for existing market leaders though, as some companies are being allowed to keep their patents. Following a number of court proceedings between Amgen and the Food and Drug Administration (FDA), the patent of blockbuster drug Enbrel has been extended to 2028. Other well-established therapies have also been allowed to keep their patents, including second-line RA treatment Actemra. However, patents are due to expire during the forecast period for major drugs such as Rituxan (Rituximab), Remicade (Infliximab), Celebrex (celecoxib) and Humira (adalimumab).
The global arthritis therapeutics market was estimated at $20.6 billion in 2010, and is expected to reach $35.8 billion in 2018 after increasing at a compound annual growth rate (CAGR) of 7.2%.
*Arthritis Therapeutics Market to 2018 – Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
This report provides an expert insight into the global arthritis market and market forecast until 2018, including in-depth analysis of the top four arthritis therapeutic indications: osteoarthritis, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape of the top companies in the market, and gives an analysis of the key trends in mergers and acquisitions, and licensing agreements involving arthritis therapies.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.
-ABOUT GBI RESEARCH-
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at firstname.lastname@example.org